Elena Rinaldi

Dr. Elena Rinaldi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2018 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ERElena Rinaldi
Elena Rinaldi
ACAlessandra Consonni
Alessandra Consonni
EGElena Guidesi
Elena Guidesi
MEMarina Elli
Marina Elli
Renato MantegazzaRenato Mantegazza
Renato Mantegazza
FBFulvio Baggi
Fulvio Baggi

1 September 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
MTMaria Cristina Tarasco
Maria Cristina Tarasco
ERElena Rinaldi
Elena Rinaldi
RFRita Frangiamore
Rita Frangiamore
FVFiammetta Vanoli
Fiammetta Vanoli
ABAlessia Berni
Alessia Berni
Paola CavalcantePaola Cavalcante
Paola Cavalcante
Efgartigimod (EFG), a biological drug targeting the IgG recycling neonatal Fc receptor (FcRn), leads to clinical improvements in patients affected by myasthenia gravis (MG), a prototypic autoantibody (Ab)-mediated autoimmune disease affecting neuromuscular junction. Because FcRn is a multifunctional protein expressed in different immune system cells, including B cells, we investigated whether FcRn blockade by EFG may have further immunologic effects, other than IgG reduction, in patients with MG. Anti-acetylcholine receptor Ab-positive (AChR-MG) patients were treated with EFG according to the GENERATIVE protocol. Clinical evaluation, IgG and autoAb quantification, and circulating T-cell and B-cell subpopulation analyses by flow cytometry were performed at different time points. The expression of regulatory plasma cell-related candidate genes (CD38, lymphocyte-activation gene 3 [LAG3], IL-12a, Ebi3) was assessed by real-time PCR in peripheral blood mononuclear cells (PBMCs) from patients on treatment and in PBMCs either untreated or in vitro treated with an EFG-mimicking anti-FcRn monoclonal Ab (mAb) or with EFG (Vyvgart). A significantly increased percentage of CD19+/CD27+ memory B cells and CD27+/CD138+ plasma cells was observed at the end of EFG treatment cycle 1 and cycle 2 in patients with AChR-MG. Plasma cell increase, maintained up to cycle 3, significantly correlated with Quantitative Myasthenia Gravis score improvement. Moreover, PBMCs from EFG-treated patients showed overexpression of CD38, LAG3, and IL-12a genes, suggesting EFG's ability to induce non-pathogenic regulatory plasma cells. This ability was confirmed in vitro, because anti-FcRn mAb-treated and EFG-treated PBMCs displayed an up-regulation of CD38 and LAG3 compared with untreated cells. Our findings indicate an unknown immunoregulatory action of EFG in patients with AChR-MG, by unraveling a drug effect on B-cell differentiation, and suggest the induction of regulatory plasma cells as a further mechanism, beyond IgG reduction, associated with clinical improvement. A deep understanding of the immunologic effects of EFG can help to optimize its usage over time in individual patients and disclose biomarkers suitable for monitoring the long-term patient-specific response.

24 October 2023 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
RFRita Frangiamore
Rita Frangiamore
ERElena Rinaldi
Elena Rinaldi
FVFiammetta Vanoli
Fiammetta Vanoli
FAFrancesca Andreetta
Francesca Andreetta
Renato MantegazzaRenato Mantegazza
Renato Mantegazza
CACarlo Antozzi
Carlo Antozzi

25 March 2025 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
CACarlo Antozzi
Carlo Antozzi
RFRita Frangiamore
Rita Frangiamore
ERElena Rinaldi
Elena Rinaldi
FVFiammetta Vanoli
Fiammetta Vanoli
FAFrancesca Andreetta
Francesca Andreetta
Renato MantegazzaRenato Mantegazza
Renato Mantegazza

3 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
CSChristos Stergiou
Christos Stergiou
RWRhys Williams
Rhys Williams
JFJennifer Fleming
Jennifer Fleming
VZVASILIKI ZOUVELOU
VASILIKI ZOUVELOU
ENElpinickie Ninou
Elpinickie Ninou
STSocrates Tzartos
Socrates Tzartos
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies targeting the neuromuscular junction (NJ) of skeletal muscles. The major MG autoantigen is nicotinic acetylcholine receptor. Other autoantigens at the NJ include MuSK, LRP4 and agrin. Autoantibodies to the intra-sarcomeric striated muscle-specific gigantic protein titin, although not directed to the NJ, are invaluable biomarkers for thymoma and MG disease severity. Thymus and thymoma are critical in MG mechanisms and management. Titin autoantibodies bind to a 30 KDa titin segment, the main immunogenic region (MIR), consisting of an Ig-FnIII-FnIII 3-domain tandem, termed I109–I111. In this work, we further resolved the localization of titin epitope(s) to facilitate the development of more specific anti-titin diagnostics. For this, we expressed protein samples corresponding to 8 MIR and non-MIR titin fragments and tested 77 anti-titin sera for antibody binding using ELISA, competition experiments and Western blots. All anti-MIR antibodies were bound exclusively to the central MIR domain, I110, and to its containing titin segments. Most antibodies were bound also to SDS-denatured I110 on Western blots, suggesting that their epitope(s) are non-conformational. No significant difference was observed between thymoma and non-thymoma patients or between early- and late-onset MG. In addition, atomic 3D-structures of the MIR and its subcomponents were elucidated using X-ray crystallography. These immunological and structural data will allow further studies into the atomic determinants underlying titin-based autoimmunity, improved diagnostics and how to eventually treat titin autoimmunity associated co-morbidities.